Jasper Therapeutics, Inc. (JSPR)
Jasper Therapeutics, Inc.
2200 Bridge Pkwy
Suite 102
Redwood City, CA 94065
United States
650 549 1400
https://www.jaspertherapeutics.com/
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 45
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Ronald A. Martell | President, CEO & Director | 1.01M | N/D | 1962 |
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder & Director | 296.3k | N/D | 1957 |
| Mr. Jeetinder Singh Mahal M.B.A. | Chief Operating Officer | 648.72k | N/D | 1973 |
| Dr. Edwin Jonathan Tucker M.D. | Chief Medical Officer | 433.33k | N/D | 1972 |
| Mr. Herbert C. Cross | CFO & Corporate Secretary | N/D | N/D | 1972 |
| Dr. Luca Di Noto Ph.D. | Senior Vice President of Technical Operations | N/D | N/D | N/D |
| Mr. David Ku M.D. | Vice President of Corporate Development, Portfolio Strategy & Management | N/D | N/D | N/D |
| Mr. Matthew Ford | Vice President of Human Resources | N/D | N/D | N/D |
| Dr. Wendy Pang M.D., Ph.D. | Senior Vice President of Research & Translational Medicine | N/D | N/D | N/D |
| Ms. Patricia Carlos | Senior Vice President of Regulatory Affairs & Quality | N/D | N/D | N/D |
Descripción
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Jasper Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
